Journal: Biological Research
Article Title: IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma
doi: 10.1186/s40659-024-00512-2
Figure Lengend Snippet: In vivo functions of miR-182-5p and R-2HG in mice model. ( A-B ) Xenograft tumor model was established in nude mice and R-2HG and/or antagomir-182-5p injection was administered as described. Tumor appearance, weight, and volume were examined. Scale bar = 1 cm. ( C ) The miR-182-5p levels in tumor tissues were examined using qRT-PCR. ( D ) Pathological alterations of tumor tissues were evaluated using H&E staining. Scale bar = 100 μm. ( E ) The protein levels of CDKN2C, CDK4, Cyclin D1, p-RB1, RB1, Bax, and Bcl-2 in tumor tissues were examined using Immunoblotting. * p < 0.05, ** p < 0.01 compared with PBS + antagomir-NC; ## p < 0.01, compared with PBS + antagomir-182-5p
Article Snippet: After that, following electrophoresis by SDS-PAGE, the separated proteins (50 µg) were electroblotted from the gel on PVDF membranes (Sigma-Aldrich). followed by an overnight treatment at 4 °C with primary antibodies: CDKN2C (ab192239, Abcam, Cambridge, USA), Cyclin D1 (60186-1-Ig, Proteintech, Wuhan, China), RB1 (ab181616, Abcam), p-RB1 (ab184796, Abcam), CDK4 (11026-1-AP, Proteintech), Bcl-2 (12789-1-AP, Proteintech), BAX (50599-2-Ig, Proteintech), and then 1.5-h interaction with secondary antibody (Abcam) at room temperature (RT).
Techniques: In Vivo, Injection, Quantitative RT-PCR, Staining, Western Blot